drugset / Trial / NCT00153049

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

NCT00153049

Phase 2 Completed 583 enrolled Boehringer Ingelheim
RandomizedFactorialDouble-blindTreatment

Summary

1. To investigate the dose response of the combination therapy, Telmisartan and Hydrochlorothiazide for the Japanese patients with Essential Hypertension. 2. To compare this dose response with that in the US study.

Timeline

Start
2004-06
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 6.25 mg
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Telmisartan Other / unclassified 40 mg
Subject Telmisartan Other / unclassified 80 mg